[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627018":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":44,"centralContacts":48,"locations":56,"responsibleParty":66,"collaborators":68,"id":72,"slug":10,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":10,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":92,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Aberdeen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Glioblastoma",null,"Participants with histologically confirmed newly diagnosed glioblastoma who have completed radical chemoradiation and are due to start adjuvant chemotherapy 4 weeks after completion of chemoradiation.",[13,14,15,16,17,18],"Other: Baseline Field-Cycling Imaging research scan","Other: Baseline 3T MRI research scan","Other: Second Field-Cycling Imaging research scan","Other: Second 3T MRI research scan","Other: Final Field-Cycling Imaging research scan","Other: Final 3T MRI research scan",[20,24,28,32,36,40],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Baseline Field-Cycling Imaging research scan","FCI scan at baseline",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Baseline 3T MRI research scan","MRI scan at baseline",[9],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"Second Field-Cycling Imaging research scan","FCI scan after three cycles of chemotherapy",[9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"Second 3T MRI research scan","MRI scan after three cycles of chemotherapy",[9],{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":10},"Final Field-Cycling Imaging research scan","FCI scan at the end of chemotherapy",[9],{"type":6,"name":41,"description":42,"armGroupLabels":43,"otherNames":10},"Final 3T MRI research scan","MRI scan at the end of chemotherapy",[9],[45],{"name":46,"affiliation":5,"role":47},"Anne Kiltie, Prof","STUDY_CHAIR",[49,53],{"name":46,"role":50,"phone":51,"phoneExt":10,"email":52},"CONTACT","+44 1224438651","anne.kiltie@abdn.ac.uk",{"name":54,"role":50,"phone":10,"phoneExt":10,"email":55},"Rafael Moleron, Dr","rafael.moleron@nhs.scot",[57],{"facility":5,"status":10,"city":58,"state":10,"zip":10,"country":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":10},"Aberdeen","United Kingdom",{"type":61,"coordinates":62},"Point",[63,64],-2.09814,57.14369,{"lat":64,"lon":63},{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[69],{"name":70,"class":71},"NHS Grampian","OTHER_GOV","100627018",false,"NCT07443176","FCI-Glioblastoma Study","Applying New MRI Technology to Improve Outcomes From Chemoradiotherapy Treatment for Adult Patients With Glioblastoma","Inclusion Criteria:\n\n* Patients scheduled to have standard adjuvant temozolomide treatment for glioblastoma, within four weeks following radical radiotherapy with concomitant temozolomide\n* 18 to 70 years old\n* Life expectancy at least 12 weeks\n* Able to undergo MRI scans lasting up to 1 hour each\n* On stable or reducing dose of steroids for at least 5 days\n* Able to provide informed consent\n* Able to understand written and spoken English\n\nExclusion Criteria:\n\n* Previous treatment for glioblastoma other than surgery and chemoradiation.\n* Previous radiotherapy to brain and\u002For prior chemotherapy for lower grade glioma.\n* Planned additional treatment with Tumor-Treating Fields\n* Previous cytotoxic wafers or implants at the time of neurosurgery\n* Uncontrolled intercurrent illness\n* Being pregnant or nursing\n* Conventional MRI contraindications\n* Known allergy to contrast agent\n* Unable to provide informed consent","ALL","18 Years","70 Years",{"count":82,"type":83},18,"ESTIMATED","OBSERVATIONAL","The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can tell the difference between tumour growth (progression) and 'pseudo-progression' (which looks like tumour but is not cancerous tissue) in patients with glioblastoma. The main question it aims to answer is:\n\n• Can FCI differentiate glioblastoma progression from pseudo-progression?\n\nParticipants will undergo a standard MRI scan and an FCI scan, three times during the study. One before starting adjuvant chemotherapy, another one after three cycles and one at the end of treatment.",[87],"Glioblastom WHO Grade 4",[9,89,90,91],"Field-Cycling Imaging","FCI","MRI","NOT_YET_RECRUITING","2026-04-29",{"date":95,"type":96},"2026-04-30","ACTUAL",{"date":98,"type":83},"2026-05",{"date":100,"type":83},"2027-12",{"name":5,"class":6},1]